Skip to main content

Advertisement

Table 1 Patient and tumor characteristics

From: Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer

  BRCA1 BRCA1 BRCA1
Mutated Non mutated Unscreened
Clinical characteristics TN Lum A HER2+ TN TN Lum A Lum B HER2+
Tumors analyzed, n 23 7 2 21 15 20 22 21
Age, years, mean 44 44 48 50 59 63 59 59
(range) (28 to 60) (29 to 71) (42 to 54) (28 to 72) (31 to 83) (43 to 86) (37 to 85) (34 to 84)
Histology, n (%)
Ductal 20 7 2 19 14 18 21 19
(87%) (100%) (100%) (90%) (93%) (90%) (69%) (90%)
Lobular 1 2 0 1 0 2 1 2
(4%) (29%) (0%) (5%) (0%) (10%) (5%) (10%)
Metaplastic 0 0 0 1 0 0 0 0
(0%) (0%) (0%) (5%) (0%) (0%) (0%) (0%)
Medullary 2 0 0 0 0 0 0 0
(8.7%) (0%) (0%) (0%) (0%) (0%) (0%) (0%)
Grade I 0 0 0 1 0 12 1 3
(0%) (0%) (0%) (5%) (0%) (60%) (5%) (14%)
Grade II 0 3 0 3 3 7 9 9
(0%) (43%) (0%) (14%) (20%) (35%) (41%) (43%)
Grade III 23 4 2 17 12 1 12 9
(100%) (57%) (100%) (81%) (80%) (5%) (55%) (43%)
Immunohistochemistry, n (%)
ER-positive, n (%) 0 7 0 0 0 20 22 12
(0%) (100%) (0%) (0%) (0%) (100%) (100%) (57%)
PR-positive, n (% 0 5 0 0 0 20 22 12
(0%) (71%) (0%) (0%) (0%) (100%) (100%) (57%)
HER2-positive, n (%) 0 0 2 0 0 0 0 21
(0%) (0%) (100%) (0%) (0%) (0%) (0%) (100%)
KI67, mean, % 42 7 47 35 48 7 44 34
P63- or EGFR- or CK14- or CK5/6-positive, n (%) 11 1 1 7 9 0 1 3
(48%) (14%) (50%) (33%) (60%) (0%) (5%) (14%)
Array CGH
Gain in 17q25.3, n (%) 20 7 2 6 4 0 3 4
(87%) (100%) (100%) (29%) (27%) (0%) (14%) (19%)
  1. TN, triple-negative; Lum, luminal; HER2+, human epidermal growth factor 2-positive; ER, estrogen receptor; PR, progesterone receptor; EGFR, epidermal growth factor receptor; CK, cytokeratin; ACGH, array comparative genomic hybridization.